ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

被引：1165

作者：

Schmoll, H. J. ^{[1
]}

Van Cutsem, E. ^{[2
]}

Stein, A. ^{[3
]}

Valentini, V. ^{[4
]}

Glimelius, B. ^{[5
,6
]}

Haustermans, K. ^{[7
]}

Nordlinger, B. ^{[8
,9
]}

van de Velde, C. J. ^{[10
]}

Balmana, J. ^{[11
]}

Regula, J. ^{[12
,13
]}

Nagtegaal, I. D. ^{[14
]}

Beets-Tan, R. G. ^{[15
]}

Arnold, D. ^{[3
]}

Ciardiello, F. ^{[16
]}

Hoff, P. ^{[17
,18
]}

Kerr, D. ^{[19
]}

Koehne, C. H. ^{[20
]}

Labianca, R. ^{[21
]}

Price, T. ^{[22
]}

Scheithauer, W. ^{[23
]}

Sobrero, A. ^{[24
]}

Tabernero, J. ^{[25
]}

Aderka, D. ^{[26
]}

Barroso, S. ^{[27
]}

Bodoky, G. ^{[28
]}

Douillard, J. Y. ^{[29
]}

El Ghazaly, H. ^{[30
]}

Gallardo, J. ^{[31
]}

Garin, A. ^{[32
]}

Glynne-Jones, R. ^{[33
]}

Jordan, K. ^{[1
]}

Meshcheryakov, A. ^{[32
]}

Papamichail, D. ^{[34
]}

Pfeiffer, P. ^{[35
]}

Souglakos, I. ^{[36
]}

Turhal, S. ^{[37
]}

Cervantes, A. ^{[38
]}

机构：

[1] Martin Luther Univ Halle Wittenberg, Dept Oncol Haematol, Halle, Germany

[2] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium

[3] Univ Comprehens Canc Ctr, Hubertus Wald Tumor Ctr, Hamburg, Germany

[4] Univ Cattolica Sacro Cuore, Policlin Univ A Gemelli, Dept Radiotherapy, Rome, Italy

[5] Uppsala Univ, Dept Radiol Oncol & Radiat Sci, Uppsala, Sweden

[6] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden

[7] Univ Hosp Leuven Campus Gasthuisberg, Dept Radiat Oncol, Louvain, Belgium

[8] Hop Ambroise Pare, Assistance Publ Hop Paris, Dept Surg, Boulogne, France

[9] Univ Versailles St Quentin Yvelines, Versailles, France

[10] Leiden Univ Med Ctr, Dept Surg, Leiden, Netherlands

[11] Univ Hosp Vall dHebron, Dept Med Oncol, Barcelona, Spain

[12] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[13] Inst Oncol, Warsaw, Poland

[14] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands

[15] Univ Hosp Maastricht, Dept Radiol, Maastricht, Netherlands

[16] Univ Naples 2, Dept Expt & Clin Med & Surg F Magrassi & A Lanzar, Div Med Oncol, Naples, Italy

[17] Hosp Sirio Libanes, Sao Paulo, Brazil

[18] Univ Sao Paulo, Fac Med, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[19] Univ Oxford, Dept Clin Pharmacol, Oxford, England

[20] Klinikum Oldenburg, Dept Oncol Haematol, Oldenburg, Germany

[21] Osped Riuniti Bergamo, Dept Haematol & Oncol, I-24100 Bergamo, Italy

[22] Queen Elizabeth Hosp, Dept Med Oncol, Woodville, SA 5011, Australia

[23] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria

[24] Osped San Martino Genova, Genoa, Italy

[25] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Med Oncol, E-08193 Barcelona, Spain

[26] Sheba Med Ctr, Div Oncol, Tel Hashomer, Israel

[27] Hosp Espirito Santo Evora, Med Oncol Serv, Evora, Portugal

[28] St Laszlo Teaching Hosp, Dept Clin Oncol, Budapest, Hungary

[29] Inst Cancerol Ouest Rene Gauducheau, Med Oncol Serv, St Herblain, France

[30] Ain Shams Univ, Dept Oncol, Cairo, Egypt

[31] INTOP, Clin Alemana, Dept Oncol, Santiago, Chile

[32] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[33] Mt Vernon Hosp, Dept Radiotherapy, Northwood HA6 2RN, Middx, England

[34] Bank Cyprus Oncol Ctr, Dept Med Oncol, Nicosia, Cyprus

[35] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark

[36] Univ Crete, Sch Med, Dept Med Oncol, Iraklion, Greece

[37] Marmara Univ Hosp, Dept Med Oncol, Istanbul, Turkey

[38] Univ Valencia, INCLIVA Hlth Res Inst, Dept Hematol & Med Oncol, Valencia, Spain

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷 / 10期

关键词：

METASTATIC COLORECTAL-CANCER; CAPECITABINE PLUS OXALIPLATIN; RANDOMIZED PHASE-III; ANGIOGENESIS INHIBITOR BEVACIZUMAB; GROWTH-FACTOR RECEPTOR; LIVER-ONLY METASTASES; GENE MUTATION STATUS; LONG-TERM SURVIVAL; 1ST-LINE TREATMENT; ADJUVANT CHEMOTHERAPY;

D O I：

10.1093/annonc/mds236

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer (CRC) is the most common tumour type in both sexes combined in Western countries. Although screening programmes including the implementation of faecal occult blood test and colonoscopy might be able to reduce mortality by removing precursor lesions and by making diagnosis at an earlier stage, the burden of disease and mortality is still high. Improvement of diagnostic and treatment options increased staging accuracy, functional outcome for early stages as well as survival. Although high quality surgery is still the mainstay of curative treatment, the management of CRC must be a multi-modal approach performed by an experienced multi-disciplinary expert team. Optimal choice of the individual treatment modality according to disease localization and extent, tumour biology and patient factors is able to maintain quality of life, enables long-term survival and even cure in selected patients by a combination of chemotherapy and surgery. Treatment decisions must be based on the available evidence, which has been the basis for this consensus conference-based guideline delivering a clear proposal for diagnostic and treatment measures in each stage of rectal and colon cancer and the individual clinical situations. This ESMO guideline is recommended to be used as the basis for treatment and management decisions.

引用

页码：2479 / 2516

页数：38

共 245 条

[1] 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours [J].

Aapro, M. S. ;

Bohlius, J. ;

Cameron, D. A. ;

Dal Lago, Lissandra ;

Donnelly, J. Peter ;

Kearney, N. ;

Lyman, G. H. ;

Pettengell, R. ;

Tjan-Heijnen, V. C. ;

Walewski, J. ;

Weber, Damien C. ;

Zielinski, C. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (01) :8-32

[2] A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer [J].

Ackland, SP ;

Jones, M ;

Tu, D ;

Simes, J ;

Yuen, J ;

Sargeant, AM ;

Dhillon, H ;

Goldberg, RM ;

Abdi, E ;

Shepherd, L ;

Moore, MJ .

BRITISH JOURNAL OF CANCER, 2005, 93 (11) :1236-1243

[3]

Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16

[4] Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases [J].

Adam, R. ;

Barroso, E. ;

Laurent, C. ;

Nuzzo, G. ;

Hubert, C. ;

Mentha, G. ;

Ijzermans, J. ;

Capussotti, L. ;

Lopezben, S. ;

Mirza, D. ;

Kaiser, G. ;

Oussoultzoglou, E. ;

Gruenberger, T. ;

Poston, G. J. ;

Skipenko, O. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[5] Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [J].

Adams, Richard A. ;

Meade, Angela M. ;

Seymour, Matthew T. ;

Wilson, Richard H. ;

Madi, Ayman ;

Fisher, David ;

Kenny, Sarah L. ;

Kay, Edward ;

Hodgkinson, Elizabeth ;

Pope, Malcolm ;

Rogers, Penny ;

Wasan, Harpreet ;

Falk, Stephen ;

Gollins, Simon ;

Hickish, Tamas ;

Bessell, Eric M. ;

Propper, David ;

Kennedy, M. John ;

Kaplan, Richard ;

Maughan, Timothy S. .

LANCET ONCOLOGY, 2011, 12 (07) :642-653

[6] Interventions for preventing neuropathy caused by cisplatin and related compounds [J].

Albers, James W. ;

Chaudhry, Vinay ;

Cavaletti, Guido ;

Donehower, Ross C. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (02)

[7] Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study [J].

Alberts, SR ;

Horvath, WL ;

Stcrnfeld, WC ;

Goldberg, RM ;

Mahoney, MR ;

Dakhil, SR ;

Levitt, R ;

Rowland, K ;

Nair, S ;

Sargent, DJ ;

Donohue, JH .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9243-9249

[8] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[9] Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer:: Results of a randomized trial [J].

André, T ;

Colin, P ;

Louvet, C ;

Gamelin, E ;

Bouche, O ;

Achille, E ;

Colbert, N ;

Boaziz, C ;

Piedbois, P ;

Tubiana-Mathieu, N ;

Boutan-Laroze, A ;

Flesch, M ;

Buyse, M ;

de Gramont, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2896-2903

[10] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].

Andre, Thierry ;

Boni, Corrado ;

Navarro, Matilde ;

Tabernero, Josep ;

Hickish, Tamas ;

Topham, Clare ;

Bonetti, Andrea ;

Clingan, Philip ;

Bridgewater, John ;

Rivera, Fernando ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116

← 1 2 3 4 5 6 7 8 9 10 →